Skip to main content
. 2024 Aug 12;48(10):1245–1258. doi: 10.1097/PAS.0000000000002297

TABLE 4.

MTAP Immunostaining Versus PD-L1 Immunostaining and CD8+ T-cell Density

PD-L1 positive (% of tumors) CD8+ density (cells/mm2)
MTAP status* n Tumor cells n Immune cells n Mean±SE
Loss 559 19.9 61.9 321 179.2±28.2
Retained 7262 15.7 71.8 3915 263.3±8.1
P 0.0125 0.0008 0.0042
*

MTAP loss: no MTAP immunostaining, MTAP retained: MTAP 1+ to 3+ immunostaining.